Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan J Russell

Showing results (111-120 of 123) with videos related to

Pageof 13
Sort By:
Biomaterials|August 25, 2014
Engineering of cell membranes with a bisphosphonate-containing polymer using ATRP synthesis for bone targetingSonia D'Souza, Hironobu Murata, Moncy V Jose, et al.
Nature|February 7, 2003
NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasiaMaya Dajee, Mirella Lazarov, Jennifer Y Zhang, et al.
The Journal of Physiology|November 22, 2016
The Ca<sup>2+</sup> sensitizer CK-2066260 increases myofibrillar Ca<sup>2+</sup> sensitivity and submaximal force selectively in fast skeletal muscleDarren T Hwee, Arthur J Cheng, James J Hartman, et al.
Muscle & Nerve|June 2, 2025
A Phase 1, Double-Blind, Placebo-Controlled Trial of Sevasemten (EDG-5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular DystrophyJoanne Donovan, Jeffrey A Silverman, Ben Barthel, et al.
Muscle & Nerve|March 18, 2014
Tirasemtiv amplifies skeletal muscle response to nerve activation in humansRichard Hansen, Khalil G Saikali, Willis Chou, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|May 18, 2012
Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosisJeremy Shefner, Jesse M Cedarbaum, Merit E Cudkowicz, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 21, 2013
Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cellsMara Fornaro, Aaron C Hinken, Saul Needle, et al.
Thorax|October 25, 2022
Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trialDivya Mohan, Harry Rossiter, Henrik Watz, et al.
Skeletal Muscle|November 15, 2018
HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injuryAndrew N Billin, Samuel E Honeycutt, Alan V McDougal, et al.
Skeletal Muscle|December 12, 2018
Correction to: HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction induced injuryAndrew N Billin, Samuel E Honeycutt, Alan V McDougal, et al.
Pageof 13

Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Biomaterials|August 25, 2014
Engineering of cell membranes with a bisphosphonate-containing polymer using ATRP synthesis for bone targetingSonia D'Souza, Hironobu Murata, Moncy V Jose, et al.
Nature|February 7, 2003
NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasiaMaya Dajee, Mirella Lazarov, Jennifer Y Zhang, et al.
The Journal of Physiology|November 22, 2016
The Ca<sup>2+</sup> sensitizer CK-2066260 increases myofibrillar Ca<sup>2+</sup> sensitivity and submaximal force selectively in fast skeletal muscleDarren T Hwee, Arthur J Cheng, James J Hartman, et al.
Muscle & Nerve|June 2, 2025
A Phase 1, Double-Blind, Placebo-Controlled Trial of Sevasemten (EDG-5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular DystrophyJoanne Donovan, Jeffrey A Silverman, Ben Barthel, et al.
Muscle & Nerve|March 18, 2014
Tirasemtiv amplifies skeletal muscle response to nerve activation in humansRichard Hansen, Khalil G Saikali, Willis Chou, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|May 18, 2012
Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosisJeremy Shefner, Jesse M Cedarbaum, Merit E Cudkowicz, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 21, 2013
Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cellsMara Fornaro, Aaron C Hinken, Saul Needle, et al.
Thorax|October 25, 2022
Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trialDivya Mohan, Harry Rossiter, Henrik Watz, et al.
Skeletal Muscle|November 15, 2018
HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injuryAndrew N Billin, Samuel E Honeycutt, Alan V McDougal, et al.
Skeletal Muscle|December 12, 2018
Correction to: HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction induced injuryAndrew N Billin, Samuel E Honeycutt, Alan V McDougal, et al.
Pageof 13